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Abstract 
The landscape of cancer care has changed dramatically over the past several decades. An 
illness that was once often fatal, now represents both an acute life threatening illness and 
a chronic condition. While there have been tremendous advancements in the treatment of 
the physiological aspects of cancer, management of related psychosocial and emotional 
issues have not seen this same progress. Limited information exists related to both the 
evaluation and outcome metrics associated with the screening and management of 
psychiatric sequelae after referral to specialized psychiatric services in cancer patient 
populations. This capstone project focused on (a) implementation of consistent use of the 
Patient Health Questionnaire 9-item (PHQ-9) survey for patients seeing a provider in the 
Norton Cancer Institute Behavioral Oncology Program (NCIBOP) at each outpatient 
visit, (b) assessment of patient outcomes for changes in depression scores, (c) review of 
clinical interventions by providers, and (d) identification of opportunities for integration 
of psychiatric practice guidelines. Evidence-based practice guidelines were incorporated. 
The major findings were sequential assessment paired with evidence-based interventions 
lead to statistically significant reduction in PHQ-9 and Distress scores.  
 Keywords: depression, distress, anxiety, coping, stress, cancer, psychosocial 
support, neoplasms, oncology, psychosocial support, psychotherapy, psychiatry, 
interventions, groups, quality of life, quality, outcomes, insurance, mental health 
coverage and patient education 
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Introduction  
In 2007, the Institute of Medicine (IOM) released a report, Cancer Care for the 
Whole Patient: Meeting the Psychosocial Health Needs, which underscored the 
importance of integrating mental health specialists into the care of cancer patients. It is 
reported that one in ten individuals have someone in their family dealing with cancer. In 
addition, it is projected that 40% of the United States population will receive a cancer 
diagnosis at some point (IOM, 2007; Meijer et al., 2011). Preliminary secondary analysis 
of the National Health and Nutrition Examination Survey (NHANES) 2003-2008 data 
revealed significant findings: (a) 9.5% of individuals with cancer meet criteria for Major 
Depression compared to 7.5% of non-cancer patients, (b) more cancer patients report 
moderate symptoms of depression (10.2% versus 7.1% respectively), and (c) cancer 
patients express more depressive symptoms (3.3 compared to 2.9) (Loprinizi & Archer-
Nanda, 2013).  
While the importance of emotional and psychological care is known, access to 
specialized psycho-oncology providers is limited, even absent in some institutions 
(Ferrell, 2005), placing responsibility to care for emotional needs on the medical team, 
nursing staff, and family caregivers. Among practices that do monitor for psychological 
distress and refer to specialized psychiatric providers, few have implemented systematic 
assessments of depression with valid and reliable tools (Carlson, Waller, Groff, Zhong, & 
Bultz, 2012; Jacobson, 2012). Opportunities exist to incorporate quality and outcome 
metrics associated with the screening and management of psychiatric sequelae in 
specialized psycho-oncology practices (Carlson et al., 2012).  
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Despite the importance of evidence-based care, there have been few studies 
addressing such interventions in the cancer patient population (Berard, 2001). This paper 
(a) describes the prevalence of depression in cancer patient populations, (b) explores the 
impact of untreated psychological and emotional sequela, (c) outlines a process 
improvement plan, and (d) defines quality metrics for the systematic assessment of 
depression in patients seen within an embedded psycho-oncology program. This paper 
reviews the integration of evidence-based practice guidelines. 
Background and Significance 
Adaptation to Illness 
At the onset of a cancer diagnosis, patients and families are faced with the 
challenge of adapting to a new illness and making a number of adjustments to meet the 
demands of the diagnosis. Growing improvements in the areas of early detection and 
prevention have changed the landscape of cancer from a disease that had been fatal in 
many instances to what is now a variety of different illnesses with a good prognosis and 
even potential for cure (IOM, 2007). With the myriad of treatment options available to 
cancer patients including chemotherapy, radiation therapy, and surgery, two-thirds of 
cancer patients live at least five years (Meijer et al., 2011). Despite the advancements in 
the physiological aspects of cancer treatments, the availability of treatment focusing on 
the psychological, social, and emotional aspects of cancer care have not kept pace (IOM, 
2007). Although psychological distress is common in cancer patients, it often goes 
unrecognized and untreated (Berard, 2001; Bottomley, 1998; Dalton et al., 2009; Hopko 
et al, 2008; Luutonen, Vahlberg, Eloranta, Hyvari, & Salminen, 2011; Meijer et al., 2011; 
Newport & Nemeroff, 1998; Ryan et al., 2005; Shimizu et al., 2010).  
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Adaptation to a new normal within the context of cancer presents many 
challenges including financial, emotional, and knowledge based stressors (IOM, 2007). 
Patients face many obstacles that may preclude successful anti-cancer efforts. Among the 
most significant barriers cancer patients report are financial problems, inadequate or 
absence of health insurance, poor communication with physicians, and lack of 
psychosocial care (IOM, 2007). Each of these barriers has the potential to adversely 
impact health outcomes (IOM, 2007). It is reported up to one-third of cancer patients 
experience persistent distress, which may even interfere with treatment (Sellick & 
Edwardson, 2007; Singer et al., 2008). Fewer than half of patients who need psychiatric 
treatment receive this care (Fromer, 2006).  
Prevalence of Depression in Oncology Patients  
Among psychological and emotional comorbidities in cancer patient populations, 
depression has received the most attention (Massie & Greenberg, 2004). Although more 
than 150 studies exist describing the prevalence of depressive disorders, this data has 
wide variability due to inconsistent methodology and differing inclusion criteria of 
depressive disorders (Dalton et al., 2009; Massie, 2004; Massie & Greenberg, 2004; 
Salvo et al., 2012). Prevalence data on depression in cancer patients ranges up to 60% in 
studies. There is clinical agreement that approximately 25% of cancer patients will 
experience a depressive episode resulting in the need for depression management 
(Bottomley, 1998; Massie, 2004; Pirl & Roth, 1999). This statistic becomes even more 
remarkable when compared to Meijer and colleagues (2011) report that the prevalence of 
depression in the general population is approximately 6%.  
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From an epidemiological perspective, enhanced understanding of cancer patient 
risks for depression and other psychological sequelae has potential to propel the inclusion 
of mental health interventions as a standard part of care onto the national agenda. There 
are no known epidemiological studies available describing the cancer patient’s increased 
risk for depression, when compared to the general population using the NHANES data in 
the United States.  
Systematic Assessment of Depression in Oncology Practices  
The diagnosis of depression can be easily overlooked and assumed by cancer 
clinicians to be an adaptation to illness with minimization of depression severity (Massie 
& Greenberg, 2004; Mystakidou et al., 2008). Since adaptation to illness can be enhanced 
through psychosocial interventions, screening individuals to determine the need for a 
psychiatric referral is an important component of care. Multiple studies have documented 
the importance of screening for and identifying patients at high risk for emotional distress 
(Bottomley, 1998; Holland et al., 2005; Hopko et al., 2008; McCorkle, Pasacreta, & Tuzh 
Tang, 2003; Meijer et al., 2011; Newport & Nemeroff, 1998; Norris, Pratt-Chapman, 
Noblick, & Cowens-Alvarado, 2011; Ransom, Jacobson, & Booth-Jones, 2006; Ryan et 
al., 2005; Salvo et al., 2012; Sellick & Edwardson, 2007; Shim, Shin, Jeon & Hahm, 
2008; Shimizu et al., 2012; Smith et al., 2009; Thewes, Meiser, Tucker, & Scnieden, 
2003; Vahdaninia, Omidvari, & Montazeri, 2010; Zabora, BrintzenhofeSzoc, Curbow, 
Hooker, & Piantadosi, 2001). Despite this evidence, screening for distress in this 
population is still not consistently done, with estimates that less than half of patients with 
distress are identified (Sellick & Edwardson, 2007). As few as 10% of patients are 
referred for specialty care with psycho-oncology providers, therefore limiting 
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opportunities to improve quality of life, treatment adherence, and potentially prognosis 
(Smith et al., 2009; Vahdaninia et al., 2010).  
There are few specialty-trained providers equipped to address the psychological 
and emotional needs of cancer patients. Although there is a significant body of literature 
supporting the psychological care for cancer patients, there is a gap with respect to 
program availability and practice (Greenberg, 2004; Pengelly & Purnell, 2009; 
Weinberger, Bruce, Roth, Breitbart, & Nelson, 2010). In recognition of this need, there 
are emerging models for enhancing collaboration between mental health and medical 
health homes (Druss & Mauer, 2010; Rhodes, Vieth, Kushner, Levy, & Asplin, 2009).  
Evidence-Based Care 
Since the release of the IOM Report, Crossing the Quality Chasm in 2001, 
emphasis has been placed on ways healthcare systems can improve care. The report 
identified safety, patient centeredness, effectiveness, timeliness, efficiency, and equality 
as six overarching aims to better meet patient needs (IOM, 2001; Stanik-Hutt et al., 
2013). Quality is representative of clinical interventions and patient perceptions of care 
that are both safe and effective (Stanik-Hutt et al., 2013). Implementation of processes 
and structured care interventions has the opportunity to improve quality and ultimately 
outcomes (Stanik-Hutt et al., 2013).  
The integration of evidence-based practice guidelines in clinical settings is one 
approach to minimizing broad variation in care delivery across clinicians (IOM, 2001; 
Oldham, Golden, & Rosof, 2008; Wobrock, Weinmann, Falkia, & Gaebel, 2009). 
Depression remains one of the most prevalent and treatable mental health disorders 
(Kroneke, Spitzer, & Williams, 2001). One approach to enhance quality in psychiatric 
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practices is through use of valid and reliable patient questionnaires to assess patient 
outcomes (Oldham et al., 2008; Valenstein et al., 2004). Among depressed adults, 
medications and psychotherapy are both evidence-based interventions for treatment and 
management (Agency for Health Care Research and Quality [AHRQ], 2009; American 
Psychiatric Association [APA], 2010, 2012; Katon & Schulberg, 1992; O’Connor, 
Whitlock, Beil, & Gaynes, 2009). 
Still, Oldham and colleagues (2008) have highlighted that psychiatry struggles as 
a discipline to adhere to evidenced-based treatment guidelines. Lack of awareness 
regarding guidelines, complexity of bio-psycho-social interactions, absence of psychiatric 
providers by region, and challenges to healthcare systems have all contributed to the 
underutilization of clinical practice guidelines (Oldham et al., 2008; Wobrock et al., 
2009). As a result, mental health interventions are often without an evidence-based 
approach despite the known importance of delivering effective and scientifically based 
care (Aarons, 2004).  
Improved care from systematic assessment. One systematic review of 
outcomes resulting from screening for depression in cancer patients exists (Meijer et al., 
2011). The study authors identified nineteen studies addressing accuracy of screening 
including one trial evaluating treatment efficacy for Major Depression. No trials 
specifically examined changes in outcomes based on the implementation of screening 
alone (Meijer et al., 2011). McMillan, Small, and Haley (2011) conducted a study that 
showed standardized systematic assessment of depression by interdisciplinary teams 
among cancer patients enrolled in hospice care was associated with significant 
improvement in depression and quality of life. Complicating the issue of systematic 
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assessment in cancer patient populations is the lack of consensus among psycho-
oncology providers regarding which psychometric instrument is most appropriate for use 
in this patient population.  
Policy Support for the Integration of Psychosocial Assessment and Management  
At a national level the Commission on Cancer (CoC) is tasking oncology 
practices with finding ways to implement distress screening and referral to specialized 
psychosocial providers by 2015 (CoC, 2012; Edge & Bura, 2011; Jacobson, 2012). 
Through collaboration and oversight since the 2007 IOM report, efforts have expanded to 
include the provision of psychosocial screening and the addition of mental health 
providers to deliver this specialty care. With the support of multiple organizations, 
including the American Psychosocial Oncology Society (APOS), the National Quality 
Forum (NQF), the CoC and the American College of Surgeons (ACoS), the International 
Psychosocial Oncology Society (IPOS), and the Quality Oncology Practice Initiatives 
(QOPI), the importance of quality mental and emotional health interventions in cancer 
populations will continue to stay on the national agenda. Current QOPI metrics require 
the identification of emotional needs by oncology providers (QOPI, 2012).  
In order to sustain and grow psychiatric programs within oncology practices, the 
identification of appropriate evaluation metrics is an important step that becomes even 
more urgent as our healthcare environment continues to change. Gaps exist in the cancer 
psychiatry literature related to the specific role of depression screening and process 
improvement initiatives for depression management in cancer patient populations. At the 
study site, Norton Cancer Institute (NCI), oncology providers assess for distress using the 
Distress Thermometer (DT) (Appendix A). Oncology providers then refer patients with 
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psychiatric needs for specialized mental health assessment by the providers. After referral 
to NCIBOP, an opportunity existed to implement systematic use of the PHQ-9 survey 
(Appendix B). The goal of this quality improvement project was to improve patient 
outcomes through sequential monitoring of depression with the PHQ-9 survey and the 
delivery of evidence-based treatment approaches.  
Purpose  
The purpose of this quality improvement capstone project was to (a) implement 
the PHQ-9 survey at each visit for patients seeing a provider in the NCIBOP, (b) assess 
patient outcomes for changes in depression scores, (c) review clinical interventions by 
providers, and (d) identify opportunities for integration of psychiatric practice guidelines.  
Review of the Literature  
A search of the databases Academic Search Premier, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), MEDLINE, PsychINFO, Psychology 
and Behavioral Sciences Collection and Newspaper Source was conducted. A 
combination of key words was used, in addition to appropriate subject terms including 
social support, psychiatry, depression, distress, anxiety, coping, stress, cancer, 
psychosocial support, neoplasms, psychotherapy, interventions, groups, quality of life, 
quality, outcomes, insurance, mental health coverage and patient education. References 
of selected studies were inspected for additional related papers. Dates were not specified 
for review based on the limited availability of relevant papers. Selection criteria included 
studies addressing the significance of psychosocial needs in cancer patients, screening 
and quality indicators related to the psychosocial care of cancer patients. Experts in the 
area of psycho-oncology were contacted for information. The recent IOM reports 
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addressing care for the whole patient, quality mental health care and crossing the quality 
chasm were also used for the purposes of this review.  
Significance of Psychosocial Needs in Cancer Patients 
Prevalence. Cancer patients report significantly higher levels of distress than 
individuals in the general population and are at increased risk for mental health problems 
including depression and anxiety disorders (Bottomley, 1998; Corboy, McDonald, & 
McLaren, 2011; IOM, 2007; Jehn et al., 2012; Trinidad, Simopoulous, & Flosnik, 2011). 
The risk for depression in cancer patients is reported to be four times greater than in the 
general population (Blake-Mortimer, Gore-Felton, Kimerling, Turner-Cobb, & Spiegel, 
1999; Bowers & Boyle, 2003; Massie & Greenberg, 2004; White & Macleod, 2002). 
Depression is reported as the number one psychiatric co-morbidity and is consistently 
rated as one of the ten most distressing symptoms for cancer patients, affecting up to 60% 
of patients during their illness (Badger, Braden, & Mishel, 2001; Bowers & Boyle, 2003; 
Breitbart, 1994; Fafouti et al., 2010; Hopko et al., 2008; Hosaka, Sugiyama, Tokuda, & 
Okuyama, 2000; Jehn et al., 2012; Massie & Greenberg, 2004; Montgomery, Pocock, 
Titley, & Lloyd, 2003; Pirl, 2004; Ross, Boesen, Dalton, & Johansen, 2002; Salvo et al., 
2012; Spiegel & Giese-Davis, 2003; Spiegel et al., 1999; Spijker, Trijsburg, & 
Duivenvoorden, 1997; White & Macleod, 2002). During advanced stages of illness the 
incidence of depression increases from 20-25% to 50-70% (Bowers & Boyle, 2003: 
Breitbart, 1994).  
Risk of undiagnosed depression. Mood disturbances such as anxiety and 
depression are often viewed as normal responses to a serious diagnosis like cancer 
(Massie & Greenberg, 2004; Spiegel & Giese-Davis, 2003) and have been identified as 
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the most common psychiatric comorbidities in cancer populations (Jehn et al., 2012; 
Salvo et al., 2012). Expected cognitive and behavioral responses often mask depression, 
causing it to remain undiagnosed and untreated in up to 80% of patients (Lloyd-Williams 
& Riddleston, 2002). There is a disparity between the number of patients experiencing 
psychological co-morbidities and the number of patients receiving appropriate referrals to 
specialized psychiatric providers.  
A systematic review of psycho-oncology literature reported 29% of cancer 
patients experienced depression (Hotopf, Chidgey, Addington-Hall, & Ly, 2002; Salvo et 
al., 2012). Researchers examining the prevalence of depression found that 29% of 524 
patients screened were depressed, a value two times greater than for non-cancer patients 
(Gruneir, Smith, Hirdes, & Cameron, 2005). Interestingly, these individuals were also 
less likely to receive antidepressant therapy (Gruneir et al., 2005). Only 30% received 
antidepressants and only 20% were seen by a mental health professional (Gruneir et al., 
2005). Remarkably, cancer patients who were not depressed were more likely to be 
followed by a psychiatric provider than those with clinical depression (Gruneir et al., 
2005).  
Hwang and colleagues (2004) in a study of veteran patients, found higher levels 
of psychological distress to be associated with an overall sense that needs were not being 
met across the care spectrum. In another study of long-term cancer survivors, those with 
higher levels of distress remembered their experience as more negative, with more 
challenges both physically and psychologically (Maliski, Sarna, Evangelista, & Padilla, 
2003).  
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Houts and colleagues (1986) assessed areas of unmet need during cancer 
treatment in both patients and caregivers. The most frequently reported unmet need was 
emotional problems reported by 25% of respondents (Houts et al., 1986). In a 
comparative study, Barg and associates (2007) used qualitative interviews to assess the 
continuance of unmet psychosocial needs. Two-thirds of these respondents reported one 
or more unmet psychosocial need during treatment (Barg et al., 2007). Psychological 
needs have been found to be second only to assistance with daily living with cancer 
patients rating psychological needs higher than information or other support needs 
(Sanders, Bantum, Owen, Thornton, & Stanton, 2010). These studies indicate that 
although efforts exist to ameliorate distress in cancer patients and meet the psychosocial 
needs of patients, there is still a lot of work to be done (Barg et al., 2007; Houts et al., 
1986; Sanders et al., 2010).  
Biopsychosocial factors associated with depression in cancer patients. 
Shimizu and colleagues (2012) presented findings from the largest study to date 
examining biopsychosocial risk factors for the development of depression in lung cancer 
patients. These researchers found that patients who reported low fighting-spirit, 
hopelessness/ helplessness, anxious preoccupation, and high scores for neuroticism were 
all at increased risk for development of depression (Shimizu et al., 2012). Patients with a 
tendency for neuroticism contribute to burden on medical systems, increase medical costs 
and have increased risk for depressive illness (Cuijpers, Smit, Penninx, de Graaf, & 
Beekman, 2010; Shimizu et al., 2012). These studies indicate the significance of unmet 
emotional needs in patients with cancer and their caregivers.  
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Consequences of Unmet Psychosocial Needs  
Left untreated, unmet psychological and emotional sequelae have significant 
consequences. Psychological impairment and the presence of mental health problems 
including depression, anxiety, post-traumatic stress symptoms (PTSS), and post-
traumatic stress disorder (PTSD) contribute to role impairment, reduced compliance with 
medical treatments, reduced quality of life, increased medical costs, prolonged 
hospitalizations, higher utilization of medical care, impacts symptom severity, and poor 
medical outcomes (Akechi et al., 2003; Badger el al., 2001; Bowers & Boyle, 2003; 
Breitbart, 1994; Greneir et al., 2005; IOM, 2007; Kissane, 2009; Montgomery et al., 
2003; Newport & Nemeroff, 1998; Passik & Breitbart, 1996; Pirl & Roth, 1999; Ransom 
et al., 2006; Ryan et al., 2005; Salvo et al., 2012; Sellick & Edwardson, 2007; Shimizu et 
al., 2012; Spiegel & Giese-Davis, 2003; Thewes et al., 2003; Valente & Saunders, 1997). 
In addition, failure to assess depression in cancer patients ignores depression as a 
treatable illness and inadequately attributes depression as a possible result of a deeper 
physiological process that may need further evaluation (Akechi et al., 2003; Bowers & 
Boyle, 2003; Breitbart, 1994; Greneir et al., 2005; Massie & Greenberg, 2004; 
Mystakidou et al., 2008; Passik & Breitbart, 1996).  
Depression contributes to impairment in personal, social, occupational, and family 
functioning (Dalton, Laursen, Ross, Mortensen, & Johansen, 2009; Hopko et al., 2008; 
Wobrock, Weinmann, Falkai, & Gaebel, 2009). Untreated distress and lack of available 
psychosocial support place families at risk for role strain and impairment in family 
functioning (Akechi, et al., 2007; Salvo et al., 2012; Vahdaninia, Omidvari, & Montazeri, 
2010). As distress exists along a continuum, waiting until severe levels of distress occur, 
ASSESSING QUALITY OUTCOMES  15 
fails to provide timely care that could prevent catastrophic results (Paterson et al., 2001). 
In severe cases, depression may even lead to an enhanced desire for sooner death or 
suicide (Akechi et al., 2007; Breitbart et al., 2000; Chochinov et al., 2005; Greneir et al., 
2005; Hooper, Vaughan, Tennant, & Perez, 1997; Kugaya et al., 1999; Suarez-Almazor, 
Newman, Hanson & Bruera, 2002).  
Cancer patients are at increased risk for suicide. Many factors contribute to this 
increased risk including pain, physical symptoms, advanced illness with poor prognosis, 
depression resulting in hopelessness, delirium and disinhibition, loss of control and 
helplessness, preexisting psychopathology, suicidal history, and inadequate social support 
(Akechi et al., 2010; Breitbart, 1994; Massie & Greenberg, 2004). Patients suffering 
severe depression are at risk for a desire for sooner death, suicide, and may even request 
physician-assisted suicide (Akechi et al., 2010; Blake-Mortimer et al., 1999; Greneir et 
al., 2005; Shimizu et al., 2012).  
 Individuals with cancer and concurrent depression and anxiety have more 
difficulty with somatic concerns, disability, more unexplained symptoms, and increased 
symptom severity (Greneir et al., 2005; IOM, 2007; Shimizu et al., 2012). Co-morbid 
psychiatric illnesses have been associated with unhealthy behaviors and reduced 
adherence to anti-neoplastic treatments (Greneir et al., 2005; IOM, 2007). Distress can 
contribute to a reduced level of hope, thus translating to a belief that cancer treatments 
are not worthwhile and contributing to poor follow-through with potentially curative 
treatments. Optimism relates to an underlying capacity for resilience, which lends to 
greater ability for problem solving, enhanced coping strategies, and an ability to find 
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meaning in illness (IOM, 2007). The presence of psychological distress reduces these 
functions and increases the risks of possible long-term complications (IOM, 2007).  
Screening for Depression using the PHQ-9 
In efforts to improve quality healthcare for mental health conditions, the IOM 
(2006) recommended clinicians use reliable and valid patient questionnaires routinely to 
assess progress and outcomes in patients. An extensive database of psychometric scales 
exists within the field of psychiatry. However, further research is needed within the field 
to strengthen the recommendation toward a single tool (Wobrock et al., 2009). A well-
studied, reliable, and valid tool for the measurement of depression is the PHQ-9 (Arroll et 
al., 2010; Dominquez-Rafer & Lin, 2011; Kronke et al., 2001). The PHQ-9 is a brief tool 
that is used with medically complex patient populations, including the cancer patient 
population (Fann et al., 2009; Manea, Gilbody, & McMillan, 2012; Oromo, Fann, 
Weymuller, Macharia, & Yueh, 2006; Thekkumpurath et al., 2011). Using a cut-off score 
of greater than or equal to 8, Thekkumpurath and colleagues (2011) reported the PHQ-9 
to be 93% sensitive and 81% specific. There is currently no benchmark data related to use 
of the PHQ-9 in cancer patient populations. An opportunity exists to establish 
benchmarks within the field of psychiatry and psycho-oncology. Studies detailed in this 
paper including the PHQ-9 and sequential assessment of depression are included in the 
literature matrix in Appendix C.  
The PHQ-9 is a brief scale by comparison to many other depression measures and 
consists of the criteria on which the diagnosis of depression is based, making this tool 
partner well with a clinical interview (Kroenke & Spitzer, 2002; Rodin et al., 2006). The 
NQF endorses outcome measurements for mental health, including measures that focus 
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on depression and the use of standardized psychometric scales, specifically the PHQ-9 
(2011). Epidemiological studies including NHANES and Behavioral Risk Factor 
Surveillance System (BRFSS) use the patient health questionnaire series (PHQ-8/9) for 
assessment of depression to gather national study data (Centers for Disease Control 
[CDC], 2012; NHANES, 2013).  
Current practice with psychometric scales. Currently broad variability exists 
among measurements used in psychiatry and psycho-oncology departments. The IOM 
report (2006) describes that as few as 27% of studies reviewed showed adherence to 
clinical guidelines and as few as 10.5% of individuals were found to receive evidence-
based interventions. A recommendation exists for patient centered decision-making and 
engagement in care, including information regarding options for and effectiveness of 
treatments (IOM, 2006).  
A better understanding of a patient’s baseline presentation allows for ongoing 
assessment of interventions and identifies opportunities to focus on targeted areas for 
clinical improvement (Oldham et al., 2008). The methodology and implementation of 
quality improvement initiatives within the mental health arena is in its very early stage of 
development. A dearth of information exists within the mental health community with 
regard to consistently used metrics and benchmarking to assess clinical and functional 
outcomes (Hermann, Leff, & Lagodmos, 2002; Valenstein et al., 2004). A gap remains 
between clinical care and evidence based practice guidelines (Hermann et al., 2006; IOM, 
2006). The APA endorses pharmacotherapy, supportive psychotherapy, and combined 
medication management and psychotherapy as efficacious in depressed patients (2010, 
2012). After integration of evidence-based practice interventions within practices, 
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anticipated outcomes include improvement in depressive symptoms, reduced recurrence 
risk, and reduction in depression related morbidity and mortality (APA, 2010).  
Theoretical Framework  
Many factors influence an individual’s ability to react to stressful situations 
including culture, ethnicity, personal history, and even personality (Folkman & 
Moskowitz, 2004; Garland & Bush, 1982). A theoretical structure assists our 
understanding of the complexities of coping and how individuals manage internal and 
external stressors (Folkman & Moskowitz, 2000; Folkman & Moskowitz, 2004). Within 
the theoretical model of stress and coping, it becomes possible to appraise the value an 
individual attributes to events, while also determining how the individual manages these 
events (Lazarus & Folkman, 1984; Folkman & Greer, 2000). This understanding provides 
a foundation for the promotion of psychological well-being through exploration of 
meaning, goal creation, and determination of patient perspective (Folkman & Greer, 
2000).  
Individual adaptation to illness exists along a continuum (Holland & Freelander, 
2006; Lazarus, 1974). The integration of illness-related factors and disease specific 
interventions impact individual coping. A myriad of coping mechanisms are necessary as 
an individual undergoes cancer treatment. Identification of patients with concurrent 
mental health disorders provides insight to individuals who may be at risk for impaired 
coping. Sequential assessment of depressive illness provides a measurement at several 
points in time and may provide insight to psychological and emotional adaptation as it 
occurs over time. Enhancement of coping strategies provides benefit to patients and 
minimizes weakened problem solving.  
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Methods and Procedures  
Model of Evidence-Based Practice  
This pilot project implemented routine assessment with the PHQ-9 to illustrate 
changes in the patients’ subjective experience. The PHQ-9 was obtained prior to the 
initiation of treatment and at each follow up appointment with NCIBOP providers to 
ascertain changes in patient symptoms. Providers in the department were educated on 
evidence-based practice interventions as part of the preparation for this quality 
improvement project. In an effort to reduce treatment variability, evidence-based 
interventions and best-practice guidelines were incorporated consistently among 
providers. Though it was beyond the scope of this pilot project, ongoing data tracking has 
continued to occur for the identification of additional practice improvement initiatives. 
Baseline data obtained through this process and quality improvement project are 
described in Appendix D.  
Intervention and Implementation Timeline 
 The implementation of this process and quality improvement project consisted of 
a number of phases (see Appendix E) leading up to this capstone project completion.  
Regular meetings began in August 2012 with the physician leader in the department, the 
Director of Quality, CNO, and NCIBOP team to provide education, rationale for 
sequential assessment with the PHQ-9, and evidence-based treatment guidelines. Initial 
exploration of the NCIBOP as a microsystem in September 2012 provided an in-depth 
understanding of the department characteristics, patient population, departmental 
processes, and preliminary departmental outcome data. Limited availability of outcome 
data reinforced the need to operationalize departmental processes and capture outcomes.  
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A comprehensive review of the literature identified the implementation of routine 
psychometric assessment with the PHQ-9 as an acceptable approach to understand 
outcomes and integrate evidence-based practice interventions. As the Norton Healthcare 
(NHC) system transitioned to the new EMR, EPIC, the PHQ-9 was incorporated into the 
visit navigator for NCIBOP providers. Initial discussion of implementing the PHQ-9 at 
initiation of care and regular intervals began in September 2012. To ensure availability of 
the PHQ-9 in the EMR, routine meetings were held with the ISA/IT team. 
Departmental processes to include the PHQ-9 at initial and follow up visits began 
in January 2013. As this project-necessitated considerable pre-work, the capstone project 
was initially discussed with the chair and committee members in October 2012. This 
capstone project was formally proposed and approved by the capstone committee in May 
2013. Ongoing visits were made to clinical managers and support teams throughout this 
project to enhance process consistency and sustain support. Regular updates were 
provided to NCI leaders to sustain support for the project. Weekly NCIBOP team 
meetings continued throughout 2013 to reinforce provider accountability for PHQ-9 
entry, documentation of the diagnostic assessment, treatment recommendations 
(pharmacological and non-pharmacological), and the plan for follow up care. The project 
budget is described in Appendix F.  
Setting and Population  
NCI is part of the NHC system and has practice sites at each of the four adult 
hospitals in Louisville, KY, as well several other locations within Kentucky and Southern 
Indiana. The practice employs 35 physicians and 22 advanced practice registered nurses 
(APRN) in medical, surgical, gynecological, radiation, orthopedic, neurological, and 
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behavioral oncology. The NCIBOP is a fully embedded psychiatric program offering a 
spectrum of services to help medically complex patients and families deal with cancer 
and related quality of life issues. The program is comprised of one physician, three 
advanced practice nurses, a part time social worker, a nurse, and two administrative staff.  
A clinical microsystem assessment was completed for the NCIBOP. Chart 
reviews of patients seen in the department revealed 59% of patients seen within the 
department were diagnosed with and being treated for a depression spectrum disorder. 
Consistent with the psycho-oncology literature, depression is the number one mental 
health diagnosis within the department.  
Sample  
 Forty-one patients seen for an initial evaluation in the outpatient setting between 
January 1, 2013 and March 31, 2013 were included; 107 were excluded. Study 
participants included males and females greater than 18 years of age with an oncologic 
diagnosis. Individuals seen through the department who did not have a cancer diagnosis 
(family members or those with benign disorders), inpatient consultations, and individuals 
seen for less than two visits were excluded.  
Intervention 
Sequential assessment of depression using the PHQ-9 was implemented. The 
information technology (IT) team was consulted to build the PHQ-9 template and 
synopsis reporting features into the Electronic Medical Record (EMR) to enhance data 
aggregation opportunities. PHQ-9 scores were entered into the EMR by the NCIBOP 
providers for comparison of subsequent scores against baseline data. Evidence-based 
practice guidelines related to the treatment and management of depression were 
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disseminated to the provider team. Practice observations and opportunities for enhancing 
care with evidence-based interventions were shared with the NCIBOP providers.  
Instrument. The PHQ-9 survey is based on the diagnostic criteria for depression 
and pairs with a clinical interview to determine the presence of depressive illness 
(Kroenke, Spitzer & Williams, 2001; Kroenke & Spitzer, 2002; Lowe, Kroenke, Herzog, 
& Grafe, 2004; NQF, 2011; Spitzer, Kroenke & Williams, 1999). The tool consists of 9 
questions with scores ranging from zero to three to determine the presence and severity of 
depressive illness. Scores 1-5 indicate minimal depression, 6-10 mild depression, 10-14 
moderate depression, 15-19 moderately severe depression and 20-27 severe depression 
(Kroenke et al., 2001; Kroenke & Spitzer, 2002; Spitzer et al., 1999). Using a cut-off 
score of 10 or higher, the tool has a high sensitivity (0.93) and specificity (0.85) and 
acceptable positive and negative predictive values (Wittkampf et al., 2009). The PHQ-9 
has demonstrated capacity to ascertain depression outcomes (Lowe et al., 2004). This tool 
is simple and cost-effective. The PHQ-9 is a free resource with no copyright or 
distribution restrictions. This one-page screening tool was acceptable and easy for both 
patients and clinicians to use.  
Data Collection  
New patient charts were reviewed for the presence of documentation of the PHQ-
9 in the EMR. Data was gathered on all newly referred patients to the NCIBOP meeting 
inclusion criterion from January 1, 2013 through March 31, 2013. A six-month 
retrospective chart review concluded September 30, 2013. Data was de-identified to 
maintain patient privacy.   
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Data aggregation was an ongoing process; the PI analyst and the department 
manager shared responsibility for data collection with quality assurance checks to ensure 
data integrity. Socio-demographic data included age, gender, race, ethnicity, educational 
level, religious affiliation, marital status, and employment status. Clinical data included 
cancer type and stage. Socio-demographic and clinical data were extracted from patient 
charts. Provider documentation in the EMR was reviewed for (a) PHQ-9 entry at each 
visit, (b) psychiatric diagnosis, (c) treatment plan and rationale (including 
psychopharmacological intervention and non-pharmacological interventions), (d) goals of 
care, and (e) plan for follow-up care. Data was aggregated and entered into a spreadsheet 
for analysis and ongoing observation.  
Data Analysis  
 Data was analyzed using Stata, College Station, TX, version 12.0. Inferential 
statistics were run with paired-samples t-test analysis to identify changes in PHQ-9 and 
distress scores pre/post NCIBOP intervention. Descriptive statistics were run for analysis 
of clinical and socio-demographic data, means (95% Confidence Interval [CI]) were 
calculated for continuous variables and proportions (95% CI) were calculated for 
categorical variables. Statistical significance was established as p < 0.05. Content 
analysis of provider feedback is described.  
Approval for Implementation 
  The study was reviewed by the Western Institutional Review Board (WIRB) and 
was granted a waiver of authorization (approval #1140717). The Norton Healthcare 
Office of Research Administration (NHORA) approved the study (NHORA #13-N0160). 
Required documentation describing the study was filed with Bellarmine University’s 
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Institutional Review Board (Non-BU IRB Submission Summary Form). Approval was 
received from the departmental providers, the capstone committee, and NCI executive 
leadership.  
Ethical considerations. This process improvement initiative was implemented to 
develop a procedure for sequential assessment with the PHQ-9 at NCIBOP provider 
visits. Completion of the PHQ-9 remained voluntary. Patients were educated regarding 
the rationale for routine assessment and quality measures to enhance the delivery of 
quality care. The Director of Quality and the PI nurse were engaged in data collection and 
auditing of study data to ensure maintenance of objectivity.  
Evaluation Plan 
 Using the initial PHQ-9 and subsequent assessment score, the impact of the 
implementation of sequential monitoring with the PHQ-9 was measured. Changes in 
PHQ-9 scores were considered a measure of clinical effectiveness. Programmatic 
outcome metrics were aggregated and ongoing process improvement efforts were 
maintained to ensure the continuation of evidence-based treatment approaches. 
Aggregated data provided an overview of patient outcomes and reflected a high level of 
quality care delivered through the department. Capability to focus on group outcomes 
rather than individual outcomes provided an optimal foundation for ongoing departmental 
quality improvement initiatives (Dulgacz, 2006; Oldham et al., 2008).   
Collateral feedback from providers about the process and utility of the project was 
obtained during provider team meetings (Appendix G). The provider team agreed the 
PHQ-9 was easy for patients to use, is important to administer routinely, and has been 
helpful in guiding treatment decisions.  
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Results  
Descriptive Analysis  
The majority of the sample was married, Caucasian females. The mean age of 
participants was 58 (SD=11.3) years of age. On average, patients were seen for 5.5 
(SD=3.1) visits. Socio-demographic characteristics are presented in Table 1.  
Table 1  
Sociodemographic Characteristics of the Study Group (N=41) 
Characteristic n Proportion (%) 
Gender  
 
 
Male 9 21.90 
Female 32 78.00 
Race  
 
 
Caucasian  36 94.70 
African American  2 5.26 
Marital status 
 
 
Married 26 65 
Divorced 5 12.5 
Widowed  4 10.0 
Separated 1 2.5 
Never Married 3 7.5 
Partner 1 2.5 
Educational attainment  
 
 
    Some high school  4 10.5 
12
th
 grade 12 31.5 
Some college 11 28.9 
Bachelor’s  8 21.0 
Post-graduate 3 7.8 
Employment status  
 
 
Employed 18 45.0 
Unemployed 4 10.0 
Retired  9 22.5 
Disabled 9 22.5 
Religions Affiliation  
 
 
Yes 21 72.4 
No 8 27.5 
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Cancer diagnostic and staging variables were obtained (see Table 2). Cancer 
staging was obtained, however caution should be taken when interpreting this variable. 
The medical record did not always clearly describe times of progression or remission.  
Table 2  
Cancer Associated Characteristics and Staging (N=41) 
Characteristic n Frequency (%) 
Cancer Diagnosis  
 
 
Hematological Malignancy  3 7.3 
GI Cancers  1 2.4 
Colon Cancer  3 7.3 
Brain Tumors 3 7.3 
Breast Cancer  14 34.1 
Gynecological Cancers  6 14.6 
Lung Cancer  4 9.7 
Pancreatic Cancer  1 2.4 
Head and Neck Cancers  1 2.4 
Other  5 12.1 
Cancer Stage  
 
 
Stage 0 1 2.4 
Stage I 9 21.9 
Stage II 13 31.7 
Stage III  4 9.7 
Stage IV 12 29.20 
Remission  2 4.80 
 
The most frequent diagnosis among participants was breast cancer (34.1%). 
Psychiatric diagnosis was most often reported as Unspecified (36.5%) or Major 
Depression (26.8%). Psychiatric diagnosis among study participants is displayed in Table 
3. Behavioral Oncology visit process variables included the frequency of completion of 
the PHQ-9 across visits.  
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Table 3  
Psychiatric Diagnostic Characteristics (N=41) 
Characteristics n Frequency (%) 
Psychiatric Diagnosis  
 
 
Depression 15 36.50 
Major Depression 11 26.80 
Unspecified Anxiety 7 17.00 
Unspecified Mood Disorder 4 9.70 
Bipolar Disorder  1 2.40 
Adjustment Disorder with Mixed Features 3 7.30 
 
At initial evaluation, the PHQ-9 was entered into the EMR 92.6% of the time; at 
follow up visits the PHQ-9 was entered 84.1% of the time (Table 4). Table 5 overviews 
provider-prescribing. Some patients received more than one psychopharmacological 
intervention.  
Table 4 
Provider Process Variables and Proportions  (N =41) 
Provider Process Variables Proportion (%) 
PHQ-9 entered at Initial Evaluation  92.68 
PHQ-9 entered at Follow Up Visit 84.19 
Psychiatric Diagnosis Documented 100 
Plan of Care and Rationale Documented 100 
Plan of Care Included Supportive Psychotherapy  100 
Plan of Care Included Medication Management 89 
 
Table 5 
Provider Prescribing Characteristics (N =41) 
Prescribing Characteristics  n Proportion (%) 
Plan of Care Included Antidepressants  31 75.60 
Plan of Care Included Mood Stabilizers 9 21.90 
Plan of Care Included Anxiolytic 20 48.8 
Plan of Care Included Sleep Aid 8 19.50 
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 PHQ-9 and distress intervention analysis.  
The forty-one participants pre/post intervention assessments were analyzed for 
changes in PHQ-9 scores (total score and individual question scores) and changes in 
distress score using the paired samples t-test. Patient initial PHQ-9 scores were compared 
with their final PHQ-9 scored. PHQ-9 total mean scores decreased from 11.34 (SD=6.1) 
pre-intervention to 8.43 (SD=5.27) post-intervention; this reduction in PHQ-9 total score 
was statistically significant (p = 0.0098). All individual PHQ-9 questions showed a 
reduction in score post-intervention. Four specific items showed statistically significant 
reduction in post-intervention scores: feeling down, depressed or hopeless (p = 0.011), 
trouble with sleep (p = 0.01), feeling bad about yourself or that you are a failure or have 
let your family down (p = 0.006), and difficulty with psychomotor agitation or retardation 
(p = 0.054).  In addition, distress scores were significantly reduced after intervention with 
NCIBOP providers (p <0.001).  
Table 6 
Mean Differences in PHQ-9 Total and Item Scores (N = 41) 
Indicator Pre-Intervention Post-Intervention t-value  p-value   
Total PHQ-9 Score  11.34 (±6.18) 8.43 (±5.27) 2.71 p = 0.009* 
Anhedonia  1.20 (±1.00) 1.14  (±0.88) 0.66 p = 0.515 
Depressed 1.51 (±1.07) 1.09 (±0.88) 2.66 p = 0.011 * 
Sleep  1.80 (±1.16) 1.24 (±1.09) 2.68 p = 0.011* 
Fatigue  2.12 (±0.93) 1.70 (±0.96) 1.83 p = 0.75 
Appetite 1.43 (±1.02) 1.21 (±1.15) 1.03 p = 0.311 
Failure  1.02 (±1.25) 0.53 (±0.83) 2.91 p = 0.006* 
Concentration  1.24 (±1.11) 0.95 (±1.18) 1.27 p = 0.209 
Psychomotor  0.76 (±0.99) 0.39 (±0.80) 1.99 p = 0.054* 
Suicide   0.17 (±0.49) 0.07 (±0.34) 1.16 p = 0.253 
Distress Score  3.80 (±3.68) 0.90 (±1.78) 5.03 p = 0.000 ** 
Note. *p <0.05. **p < 0.01.   
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Discussion 
Evidence-Based Practice Interventions  
 Previous study has identified variances among cancer patients diagnosed with 
depression and those who receive antidepressants (Gruneir et al., 2005). In 2006, the 
IOM reported less than 11% of patients receive interventions based on evidence. The 
integrated psycho-oncology program in this study implemented a model for evidence-
based practice. Providers were accepting of systematic screening with the PHQ-9. 
Review of provider documentation revealed adherence to evidence-based interventions; 
100% of patient charts reviewed included a psychiatric diagnosis, 89% of patients agreed 
to medication interventions for clinical disorders, 100% of patients received supportive 
psychotherapy, and 100% of the reviewed notes explained the treatment rationale and 
plan for follow up. Evidence-based care delivered in this program far exceeds the 
national norm described in the IOM (2006) report. Statistically significant reductions in 
both PHQ-9 score and Distress scores reflect high quality care. Quality care was 
delivered similarly across several practice sites and multiple providers.  
The CNO and the Director of Quality remained engaged and supportive 
throughout the project. The project was viewed as an important quality improvement 
initiative for the cancer institute and was adopted as one of the quality studies for the 
Cancer Committee and accreditation through the CoC. No significant barriers were 
encountered. Availability of outcome data reflecting a significant improvement in PHQ-9 
scores from initial assessment has been helpful in reinforcing the importance of 
maintaining processes for quality care delivery. 
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Strengths and Limitations   
This study had a number of methodological strengths and weaknesses. The dual 
role of the principle investigator and program provider posed a potential study weakness; 
audits to ensure data quality by the PI nurse and Director of Quality minimized this study 
risk and interpretation bias. Despite the small sample size, sequential assessment with the 
PHQ-9 and delivery of evidence-based interventions seems to be associated with 
reduction in depression. The homogeneity of the sample is both a strength and weakness; 
study data is primarily relatable to women with breast cancer. Further investigation with 
larger samples would be helpful to determine generalizability. Absence of a comparison 
group and baseline data poses an additional study limitation.  
The clinical setting allowed for significant control of the processes and range of 
clinical interventions delivered by program providers. NCIBOP providers sustained 
engagement with this initiative and belief in the benefit of consistency among providers; 
this may be due to the small size of the department and may take more time to adapt into 
larger practice settings. Opportunities continue to exist to enhance front-end processes 
with the provision of the PHQ-9 survey to patients upon arrival for appointments.  
Recommendations  
 The implementation of quality and process improvement initiatives provides a 
foundation for aggregating department specific outcomes. Study data may be helpful for 
establishing benchmarks internally and with other psycho-oncology practices. Multi-
center collaboration studies are needed to more clearly understand the unique needs of 
specialized patient populations. As the national healthcare agenda continues to evolve, 
metric based outcome studies will be necessary to articulate the importance of mental 
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health interventions. Continual tracking should ensue beyond the study period to assure 
the continuation of evidence-based practice and screening with the PHQ-9. With the 
advent of the medical home and further integration of mental health providers into 
medical settings, the capacity to fully explain the added value of specialized mental 
health services and to advocate for these services is more important than ever before.  
Future Research 
Future studies with larger samples across multiple cancer centers are needed to 
fully understand the impact of sequential assessment of depression with PHQ-9 on 
outcomes. Additional study of prevalence and penetrance of psycho-oncology services 
within this cancer center may be helpful. Preliminary analysis of the NHANES data 
described in this study revealed statistically significant differences in the rates of cancer 
patients meeting criterion for major depression when compared to non-cancer patients; 
gaps in this area of the literature reinforces the priority for epidemiological study in 
psycho-oncology. Additional study evaluating reduction in depression scores and the 
impact this has on quality of life are needed. 
Conclusions 
 As bio-medical approaches to treatment continue to advance, psychosocial 
interventions supporting quality of life will have to keep pace (IOM, 2007). As the field 
of psycho-oncology continues to grow, oncology providers will need to support thorough 
psychosocial assessments and psychiatric measures to fully describe patient and program 
outcomes. With the inclusion of psychosocial measures for accreditation at the majority 
of cancer centers nationwide, cancer centers will be pushed to screen for psychological 
sequelae as a routine part of care (COC, 2012; Jacobson, 2012; Jacobson, 2013). Once 
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patients enter care with specialized psychiatric providers, the ability to measure outcomes 
is important for describing clinical care, advocating for resources, and sustaining 
psychiatric programs. Use of the PHQ-9, a reliable and valid measure of depression 
severity (Kroneke et al., 2001), at routine intervals in specialized cancer mental health 
settings, provides a metric for ongoing analysis of patient outcome data. Evidence 
supports the use of validated screenings as a way to minimize treatment variability. 
Combined with comprehensive medication management and psychotherapeutic 
interventions, patients are likely to have the most optimal outcomes (AHRQ, 2009; NQF, 
2011). 
Findings from this study are suggestive that the implementation of quality 
metrics, sequential assessment with validated tools, and the integration of evidence-based 
treatment guidelines are feasible. Aggregation of patient outcome data showed 
statistically significant improvement in PHQ-9 scores after intervention with the 
NCIBOP providers when using evidence-based treatment approaches. With the evolution 
of healthcare policy and a rising demand for quality, the establishment of standards for 
care and the inclusion of quality metrics are necessary to effectively measure patient 
outcomes.   
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Appendix A 
Distress Thermometer  
SCREENING TOOL FOR MEASURING DISTRESS 
 
Instructions:  
First please circle the number (0-10) that best describes how much distress you have been 
experiencing in the past week including today. 
 
Extreme distress 
 
 
 
No Distress        
 
We want to make sure we are providing you with excellent care. This survey helps us to assess your 
needs; if you would like to see either a social worker or Behavioral Oncology provider, please let us 
know. You may contact the Behavioral Oncology Program at (502) 899-2673.  
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Appendix B  
 Patient Health Questionnaire (PHQ-9) 
 
Patient Name: _______________________________________   Date: ________ 
 
Over the last 2 weeks, how often have you been bothered by any of the following 
problems?  
(use “✓” to indicate your answer)  
 
Not Several   More than  Nearly         
at all     days   ½ the days  everyday 
1. Little interest or pleasure in doing things                  0    1      2     3             
2. Feeling down, depressed, or hopeless       0    1      2  3 
3. Trouble falling/staying asleep or sleeping too much   0    1      2  3 
4. Feeling tired or having little energy       0    1       2  3 
5. Poor appetite or overeating         0    1      2  3 
6. Feeling bad about yourself – or that you are      0    1      2  3         
a failure or have let yourself or your family down  
7. Trouble concentrating on things, such as       0    1       2  3       
reading the newspaper or watching television  
8. Moving or speaking so slowly that other people      0     1      2  3        
could have noticed. Or the opposite - being so fidgety              
or restless that you have been moving around more            
than usual  
9. Thoughts that you would be better off dead or of      0     1       2  3 
hurting yourself in someway 
     Add columns  
     TOTAL  
If you checked off any problems, how difficult have these problems made it for you to 
do your work, take care of things at home, or get along with other people? 
Not difficult at all Somewhat difficult Very difficult  Extremely difficult 
(Healthcare Professional: For interpretation of TOTAL, see accompanying scoring 
card).      
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among studies. 
Multiple 
screening 
tools, unclear 
if best choice 
exists.  
Strong 
evidence. 
Level 1. 
Rodin, & 
Supportive 
Care 
Guidelines 
Group of 
Cancer Care 
Ontario 
Program in 
Evidence-
Based, 
(2007). 
Study was 
conducted to 
evaluate the 
efficacy of 
pharmacologi
cal and non-
pharm 
interventions 
for 
depression in 
cancer 
patients.  
Systematic 
Review  
Inclusion: 
systematic 
reviews, meta-
analysis, 
evidence-
based practice 
guidelines, or 
RCT/ non-
randomized 
observational 
trials. All 
studies had 
outcome 
Variable by 
study, no 
pooled 
sample 
provided. 
Multiple 
statistical 
analysis run 
due to study 
complexity.  
Limited 
information 
about 
efficacy for 
pharmacologi
cal and 
psychosocial 
interventions 
in cancer 
patients. 
Evidence 
from study 
includes 
11 trials included 
with 
pharmacological/ 
non-pharm 
interventions. 
Cochrane systematic 
review- based on 
healthy adults 
included.  
No systematic 
screening tool 
in place to 
identify 
depression or 
sequentially 
monitor. 
Identifies 
literature gap; 
also Cochrane 
review for 
depression 
management is 
Strong 
evidence. 
Level 1.  
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First 
Author/ 
Year 
Purpose / 
Aims 
Study 
Design 
Instrument Sample size 
/ Statistics 
Results Conclusions / 
Recommendations  
Limitations Quality of 
evidence 
measure of 
depression 
symptoms.  
deductions 
made from 
healthy 
adults.  
based on 
healthy 
individuals, 
not unique 
needs of 
cancer 
patients.  
Thekkumpur
ath, P. 
(2011). 
Screening for 
major 
depression in 
cancer 
outpatients: 
the diagnostic 
accuracy of 
the 9-item 
patient health 
questionnaire 
Systematic 
Review  
PHQ-9 4,264 
pooled 
patients. 
ROC 
analysis.  
PHQ-9 with a 
cut-off score 
of ≥ 8 had 
acceptable 
sensitivity 
and 
specificity to 
identify 
MDD in 
cancer 
patients.  
PHQ-9 is an 
acceptable tool for 
use in cancer patients 
and takes only 
approximately 2 
minutes to complete. 
Self response 
bias. Two 
stage process 
to determine 
presence of 
depression 
may have 
missed cases 
of MDD. Was 
not inclusive 
of all cancer 
types. Limited 
clinical data to 
identify 
confounders. 
Delayed SCID. 
Strong 
evidence. 
Level 1.  
Thewes & 
Greater 
Southern 
Area Health 
Service 
Screening 
Collaborativ
e (2009). 
To determine 
feasibility 
and 
usefulness of 
depression 
screening in 
cancer 
outpatient 
setting. 
Pilot Study  Distress 
Thermometer 
(DT) 
43 
participants. 
Univariate 
and 
multivariate 
analysis.  
44% met 
criteria for 
having 
additional 
needs for 
psychosocial 
care with 
validated DT. 
86% 
sensitivity, 
Though screening 
with DT did not 
increase the number 
of referrals, it did 
reduce the amount of 
time before patients 
were offered referral.  
Very small 
sample size.  
Fair 
evidence. 
Level 3.  
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First 
Author/ 
Year 
Purpose / 
Aims 
Study 
Design 
Instrument Sample size 
/ Statistics 
Results Conclusions / 
Recommendations  
Limitations Quality of 
evidence 
77% 
specificity. 
Screening did 
not increase 
referral rates, 
but did 
reduce time 
to referral for 
specialized 
care.  
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Appendix D 
Quality Improvement Evaluation Plan 
Outcome/ 
Process Indicator 
Measure/ 
Operational Definition 
Rationale for 
Measure 
Selection 
Data Collection 
Approach 
Benchmark Improvement Goal 
PHQ-9 Questionnaire is 
administered to each 
patient at initiation of 
care with the department.  
 
(Assessment Measure)  
 
(Long term goal) 
 Percentage of patients with the 
principle diagnosis of depression that 
has the PHQ-9 documented at time of 
initial evaluation.  
 
Numerator: Number of new patients 
who are seen for depression who fill 
out the PHQ-9 at the first visit during 
a specified time period (example: 
January 1 through February 1).  
 
Denominator: The number of new 
patients seen in the department 
during the specified time period with 
the diagnosis of depression. 
 
Exclusions: individuals with primary 
bipolar disorder, personality disorder 
or those who have died (NQF, 2011).  
PHQ-9 is a 
reliable, 
validated and 
standardized 
tool. The survey 
is brief 
compared with 
other 
psychometric 
measures.  
(Kroenke et al., 
2001; Kroenke, 
& Spitzer, 
2002; NQF, 
2011) 
 The assigned 
provider will enter 
PHQ-9 data into 
the EMR.  
 
PI nurse will 
complete ongoing 
PI with data 
analysis and 
aggregation 
monthly by the 
quality director. 
Internal goal. No 
benchmark data is 
available in the 
cancer patient 
population. 
 
 
Baseline Result: 92% 
 
Goal: Maintain > 90% PHQ-9 entered at 
the initial outpatient visit 
Reassessment with PHQ-
9 
 
(Assessment Measure) 
 
(Long term goal) 
 
 
 
Percentage of patients receiving 
treatment with BHONCP who 
complete PHQ-9 reassessments.  
 
Numerator: Number of patients seen 
for depression in the department who 
fill out the PHQ-9 at three-month 
follow-up.  
 
Denominator: The number of follow 
Changes in 
score on 
standard 
psychiatric 
rating scale. 
This is a 
patient- 
centered 
measure, which 
also impacts 
The assigned 
provider will enter 
data into EMR, 
making accessible 
for data collection.  
 
PI nurse will 
complete ongoing 
PI with data 
analysis and 
Internal goal.  
No benchmark data 
is available in the 
cancer patient 
population. 
Baseline Result: 84%  
 
Goal: Increase to 90% PHQ-9 entered at 
follow-up visits  
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Outcome/ 
Process Indicator 
Measure/ 
Operational Definition 
Rationale for 
Measure 
Selection 
Data Collection 
Approach 
Benchmark Improvement Goal 
up patients who are seen within the 
department for depression at three 
months.  
 
Exclusions: individuals with primary 
bipolar disorder, personality disorder 
or those who have died (NQF, 2011). 
patient safety, 
efficiency, 
equity and 
timeliness 
(IOM, 2006).  
 
Engages patient 
in symptom 
assessment and 
treatment 
planning.  
(IOM, 2001) 
aggregation 
monthly by the 
quality director. 
Patients with Major 
Depressive disorder 
receive an adequate 
medication trial  
 
(Treatment Measure/ 
Process measure)  
 
(Medium term goal) 
 
 
Proportion of patients who are 
prescribed an antidepressant for 
treatment.  
 
Numerator:  
Number of patients who meet criteria 
for depressive illness who are on a 
medication for a specified time 
frame.  
 
Denominator: Number of patients 
who meet criteria for depression who 
are seen by the department during a 
specified time frame.  
 
Exclusions: individuals with primary 
bipolar disorder, personality disorder 
or those who have died (NQF, 2011). 
Depression is 
treatable with 
anti-depressant 
medication.  
 
Effective and 
Equitable care 
are two of the 
aims of the 
IOM report 
(2001; 2006). 
Ensuring that 
patients have 
equal access to 
medication and 
are provided 
services based 
on knowledge.  
 
A good 
evidence level 
is described 
Medication is 
entered into the 
EMR and can be 
found on the 
patients updated 
medication list.  
 
Data collection will 
occur through PI 
audits of patient 
charts to establish 
results and identify 
practice variances.  
Internal goal; no 
benchmark data 
available.  
 
 
 
Diagnosis was recorded on 100% of 
patients.   
 
When indicated, medications were 
offered and prescribed (89% agreed to 
medications). 
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Outcome/ 
Process Indicator 
Measure/ 
Operational Definition 
Rationale for 
Measure 
Selection 
Data Collection 
Approach 
Benchmark Improvement Goal 
through the 
AHRQ- Level 
A rating 
(AHRQ, 2009; 
Katon & 
Schulberg, 
1992; 
O’Connor et al., 
2009) 
 
Patients with Major 
Depressive disorder 
receive Supportive 
Psychotherapy or 
another validated therapy 
modality  
 
(Treatment Measure/ 
Process Measure)  
 
(Medium term goal) 
 
Portion of patients who receive 
psychotherapy.  
 
Numerator: Number of patients who 
receive psychotherapy.  
 
Denominator: Number of patients 
with a depression diagnosis seen 
within the department during the 
specified time frame.  
 
Exclusions: individuals with primary 
bipolar disorder, personality disorder 
or those who have died (NQF, 2011). 
Several types of 
psycho-therapy 
including 
Cognitive 
Behavioral 
Therapy, 
Supportive 
Therapy and 
Inter-Personal 
therapy have 
shown efficacy 
in the treatment 
of depression 
(American 
Psychiatric 
Association 
[APA], 2012; 
AHRQ, 2012).  
 
A good 
evidence level 
is described 
through the 
AHRQ- Level 
The treating 
provider will enter 
the therapy 
modality into the 
EMR; data 
accessible to the PI 
nurse and director 
of quality through 
the EMR.  
 
Data collection will 
occur through PI 
audits of patient 
charts to establish 
results and identify 
practice variances 
as directed by the 
quality team.  
Internal goal; no 
benchmark data 
available.  
 
 
 
100% of charts reviewed stated delivery 
of supportive psychotherapy.  
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Outcome/ 
Process Indicator 
Measure/ 
Operational Definition 
Rationale for 
Measure 
Selection 
Data Collection 
Approach 
Benchmark Improvement Goal 
A rating 
(AHRQ, 2009; 
APA, 2012). 
Patients report improved 
symptom status with 
either individual or 
combined psychotherapy 
and medications 
 
(Outcome measure) 
 
(Long term goal) 
 
Portion of patients who are receiving 
trials on antidepressant therapy with 
or without combined psychotherapies 
who show improvement in PHQ-9 
scores over a specified period of 
time.  
 
Numerator:  
People who show a reduction in 
PHQ-9 scores at six months.  
 
Denominator: People who are treated 
for six months from initial treatment 
for depression who are receiving 
psychotherapy with or without 
medication management with initial 
and six month PHQ-9 scores.  
 
Exclusions: individuals with primary 
bipolar disorder, personality disorder 
or those who have died (NQF, 2011). 
This outcome 
relates to 
patient centered 
care, one of the 
six quality 
domains 
identified by the 
IOM (2001, 
2006).  
Additionally 
this relates to 
the delivery of 
effective, 
efficient and 
safe care as 
described by the 
IOM; with 
integration of 
evidence-based 
practice (2006).  
 
Aggregated PHQ-9 
scores from initial 
through follow ups 
available on flow 
sheet in EMR.  
 
 
Results will be 
aggregated on a 
quarterly basis to 
capture department 
outcomes with 
focus on system 
improvement, 
rather than 
individual reports.  
 
Internal goal; no 
benchmark data 
available.  
 
 
Total PHQ-9 mean scores decreased 
from 11.34 (6.1) pre-intervention to 8.43 
(5.27) post-intervention (p < 0.05).  
 
Patients studied revealed EBP 
interventions led to statistically 
significant improvement in PHQ-9 
scores.  
 
Provider will use PHQ-9 
tool to modify treatment 
plan if score rises  
 
(Outcome Measure)  
 
(Long term goal) 
 
Portion of patients who are receiving 
trials on antidepressant therapy with 
or without combined psychotherapies 
who show increase in PHQ-9 scores 
over a specified period of time.  
 
Numerator:  
People who show an increase in 
PHQ-9 scores at six months.  
 
This relates to 
the delivery of 
effective, 
efficient and 
safe care as 
described by the 
IOM (2006). 
This supports 
the integration 
of evidence-  
Aggregated PHQ-9 
scores from initial 
through follow ups 
available on flow 
sheet in EMR.  
 
Evidence of 
provider 
integration of score 
and formulation of 
Internal goal; no 
benchmark data 
available.  
 
100%  
 
Patient charts were reviewed, in patients 
where depression scores worsened, 
providers made adaptations to the 
treatment regimen 
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Outcome/ 
Process Indicator 
Measure/ 
Operational Definition 
Rationale for 
Measure 
Selection 
Data Collection 
Approach 
Benchmark Improvement Goal 
Denominator: People who are treated 
for six months from initial treatment 
for depression who are receiving 
psychotherapy with or without 
medication management with initial 
and six month PHQ-9 scores.  
 
Exclusions: individuals with primary 
bipolar disorder, personality disorder 
or those who have died (NQF, 2011). 
based care with 
use of 
standardized 
instruments to 
inform care 
decisions.  
treatment plan 
based on patient 
results will be 
available in 
provider 
documentation.  
 
Results will be 
aggregated on a 
quarterly basis to 
capture department 
outcomes with 
focus on system 
improvement, 
rather than 
individual reports.  
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Appendix E  
Timeline  
Process 
steps/  Date  
 
 
 
 
November, 
2011 
 
 
 
 
April, 
2012 
 
 
 
 
October 
1, 2012 
 
 
 
 
November, 
2012 
 
 
 
 
January 1, 
2013 
 
 
 
 
March 1, 
2013 
April 15, 
2013 
May 15, 
2013 
June 1, 
2013 
July 15, 
2013 
August 1, 
2013 
September 
30, 2013 
October 15, 
2013 
October 20, 
2013 
November 1, 
2013 
November 
15-
November 
30, 2013 
December, 
2013 
December 
19, 2013 
DNP Capstone Project  
                  
Initial review of 
Psycho-oncology 
Literature 
                  
Preliminary Budget                   
Identify Gaps in 
Psycho-oncology 
                  
Engagement of 
Clinical Team  
                  
Build PHQ-9 into 
EMR  
                  
Organizational 
Assessment 
                  
Clinical Microsystem 
Assessment  
                  
Proposed Evaluation 
Plan 
                  
Preliminary System 
Quality Meetings 
                  
 Leadership 
Engagement in 
Proposed Project  
                  
Written Goals and 
Project Mission 
Statement  
                  
Finalized Project 
Proposal/ Evaluation 
Plan 
                  
Budgetary Refinement 
                  
Meetings with 
CNO/Quality and 
Clinical Teams 
                  
Approval from CNO, 
Quality  
                  
IRB/NHORA 
Approval 
                  
Data Collection                    
Data Analysis                   
Capstone Paper 
                  
First draft integrating 
Analysis/ Recs   
                  
Capstone paper to 
committee for 
revisions   
                  
Integration of 
Revisions   
                  
Capstone Presentation                    
Graduation                    
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Appendix F 
Budget  
Expense Item Quantity Unit Cost 
Total Cost 
Monthly 
Annualized 
Expense 
 Office 
Supplies  
Copies for PHQ-
9 Scales for 
Patients 150 $0.20 $30 $360 
Copies for 
Educational 
Materials 
(Leadership and 
Departmental) 200 $0.20 $40 $480 
Mental Health 
Quality Resource 
Books 2 $60 $120 $120 
Subtotal    $960 
Wages  
Manager/ Senior 
Leadership 
Salaries  640 $50 $2667 $32,000 
Quality 
Personnel 
Salaries 20 $45 $75 $900 
PI Nurse Salary  120 $32 $320 $3840 
Provider Salary 
Dollars  50 $62 $258 $3100 
EPIC Staff 
Salary  40 $35 $117 $1400 
Subtotal     $41,240 
Survey 
Instrument  PHQ-9 No Cost  $0 $0 $0  
 Subtotal     $0 
Total Cost      $42,200 
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Appendix G 
Provider Feedback on PHQ-9 Integration (Focus Group) 
1. Do you find the PHQ-9 easy for patients to use?  
2. How important do you think it is to administer the PHQ-9 at every patient visit?  
3. How important has the PHQ-9 been in guiding treatment decisions?  
4. What value do you see in using the PHQ-9 to benchmark with similar programs?  
5. Do you think information from the PHQ-9 will be useful in establishing 
department guidelines?  
 
 
